Cancer drug company Epizyme prices IPO, begins trading

Epizyme Inc. has priced its initial public offering at $15 a share –— the top of the expected range — and will start trading on the Nasdaq Friday under the ticker symbol, "EPZM...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.